Status:

RECRUITING

Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

Lead Sponsor:

Central Hospital, Nancy, France

Conditions:

Dermatomyositis

Eligibility:

All Genders

Brief Summary

Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and ch...

Eligibility Criteria

Inclusion

  • Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification

Exclusion

  • Patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of dermatomyositis)
  • Patient with antisynthetase syndrome

Key Trial Info

Start Date :

October 1 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 30 2024

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06004817

Start Date

October 1 2023

End Date

September 30 2024

Last Update

August 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chu Nancy

Nancy, France

Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis | DecenTrialz